Novel coronavirus infection
Conditions
Interventions
Crocin tablets group:Taking Crocin tablets (12mg/ tablet) orally, 4 tablets/time, 3 times/day after each meal for 7 days
Placebo group:Taking placebo tablets (12mg/ tablet) orally, 4 tablets/time, 3 times/day after each meal for 7 days
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Patients diagnosed with mild and moderate novel coronavirus infection, and the respiratory symptoms have disappeared or eased; (2) The main clinical symptoms were heart involvement such as palpitations and chest tightness; (3) Patients meet the diagnostic criteria of "blood stasis syndrome" in the traditional Chinese medicine (TCM) system; (4) Age 18-65 years old (including 18 years old and 65 years old; (5) Sign the subject's informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients diagnosed with severe or critical forms of novel coronavirus infection; (2) Chest tightness and palpitations caused by chronic lung diseases or cardiovascular and cerebrovascular diseases, such as chronic obstructive pulmonary disease, asthma, chronic pulmonary heart disease, coronary atherosclerotic heart disease, chronic cardiac insufficiency, atrial fibrillation, hypertension, etc.; (3) Complicated with serious lung diseases, such as lung cancer and tuberculosis; (4) Complicated with serious malignant tumors, diseases of the blood and hematopoietic system, gastrointestinal diseases or other serious or progressive diseases of the system; Or combined with severe mental illness, severe cognitive dysfunction, etc., unable to cooperate or unwilling to cooperate; (5) Hepatic and renal insufficiency: ALT or AST > 2 times the upper limit of normal reference value; And/or serum creatinine > 1.5 times the upper limit of normal reference value, or eGFR 10.0×10^9/L; And/or neutrophil (N) classification >80%; (7) Have taken drugs similar to the functional indications of the experimental drugs within the past 1 month; (8) With a long history of alcohol or drug abuse; (9) Women who are pregnant or planning to become pregnant, breastfeeding women; (10) Combined with bleeding disease or bleeding tendency; (11) People who are allergic or allergic to known ingredients of the drug; (12) Participants in other drug clinical trials within the past 1 month; (13) Subjects deemed unsuitable for clinical trials by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total effective rate of TCM syndrome score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Myocardial markers test series;TCM syndrome score;recurrence rate; | — |
Countries
China
Contacts
Public ContactLiu Wei
West China Hospital of Sichuan University
Outcome results
None listed